Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements. Therefore, the Zacks rating upgrade for Relay Therapeutics basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. Most Powerful Forc
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.MarketBeat
- Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free SurvivalGlobeNewswire
- Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer SymposiumGlobeNewswire
RLAY
Earnings
- 11/6/24 - Beat
RLAY
Sec Filings
- 12/18/24 - Form 4
- 12/16/24 - Form 144
- 12/11/24 - Form 8-K
- RLAY's page on the SEC website